GlassScriptPhysician profile
Rachel Rogers
NPI 1013438068
$7,086.42
in general payments reported to CMS, 2019-2025
44 companies · $987 in 2025
The $987 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $197 · 2021: $1,004 · 2022: $1,725 · 2023: $1,600 · 2024: $1,418 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,203.90 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $975.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $865.84 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.25 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $332.94 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $328.92 | 2020-2025 | Trelegy Ellipta |
| Pfizer INC. | $304.40 | 2021-2025 | |
| Amgen INC. | $258.27 | 2021-2023 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.67 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $220.44 | 2021-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $159.57 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $155.90 | 2020-2024 | Eliquis |
| Mylan Specialty L.P. | $153.69 | 2022-2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $147.80 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.09 | 2022-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.